Chronic hypertension leads to hyperinsulinemia in Sprague-Dawley rats treated with nitric oxide synthase inhibitor

American Journal of Hypertension

Volumn 11, Issue 9, 1998, Pages 1129-1133

  Erlich, Yael ^a   Rosenthal, Talma ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Chronic hypertension; Hyperinsulinemia; N(G) nitro L arginine methyl ester (L NAME); Verapamil

Indexed keywords

INSULIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; VASODILATOR AGENT; VERAPAMIL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITOR COMPLEX; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032168541     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00089-2     Document Type: Article

References (50)

1. 1. Ferrannini E: Metabolic abnormalities of hypertension. A lesson in complexity. Hypertension 1991;18:636-639.
2. 2. Panza JA, Quyyumi AA, Brush JE Jr, et al: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27.
3. 3. Lockette W, Otsuka Y, Carretero O: The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension 1986;8(suppl II):II61-II66.
4. 4. Creager MA, Gallagher SJ, Girerd XJ, et al: L-Arginine improves endothelium dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-1253.
5. 5. Shimokawa H, Vanhoutte PM: Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res 1989;64:900-914.
6. 6. Williams SB, Cusco JA, Roddy MA, et al: Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus. J Am Col Cardiol 1996;27:567-574.
7. 7. Calver A, Collier J, Vallance P: Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin dependent diabetes. J Clin Invest 1992;90:2548-2554.
8. 8. Kamata K, Miyata N, Kasuya Y: Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 1989;97:614-618.
9. 9. Rees DD, Palmer RMJ, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
10. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991;261:F1033-F1037.
11. 11. Wang YX, Gavras I, Wierzba T, et al: Inhibition of nitric oxide, bradykinin and prostaglandins in normal rats. Hypertension 1992;19(suppl II):II-255-II-261.
12. 12. Nafrialdi N, Jover B, Mimran A: Renin angiotensin system in the pressor effect of acute N-omega-nitro-L-arginine methyl ester. J Hypertens 1993;11(suppl 5): S324-S325.
13. 13. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281.
14. 14. Ribeiro MD, Anttunes E, de-Nucci G, et al: Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992;20:298-303.
15. 15. Morton JJ, Beattie EC, Speirs A, et al: Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens 1993;11:1083-1088.
16. 16. Bank N, Aynedjian HS, Khan GA: Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension 1994;24:322-328.
17. 17. Manning RD Jr, Hu L: Nitric oxide regulates renal hemodynamics and urinary sodium excretion in dogs. Hypertension 1994;23:619-625.
18. 18. Rees DD, Palmer J, Schulz R, et al: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-752.
19. 19. Vallance P, Collier PJ, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;11:997-1000.
20. 20. Gardiner SM, Compton AM, Bennett T, et al: Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990;15:486-492.
21. 21. Sigmon DH, Beierwaltes WH: Nitric oxide influences blood flow distribution in renovascular hypertension. Hypertension 1994;23(suppl I):I-34-I-39.
22. 22. Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. New Engl J Med 1990;323:27-36.
23. 23. Laakso M, Edelman SV, Brechtel G, et al: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. J Clin Invest 1990;85:1844-1852.
24. 24. Ganrot PO: Insulin resistance syndrome: possible key role of blood flow in resting muscle. Diabetologia 1993; 36:876-879.
25. 25. Erlich Y, Rosenthal T: Contribution of nitric oxide to the beneficial effect of enalapril in fructose induced hyperinsulinemic rats. Hypertension 1996;28:754-757.
26. 26. Rhaleb NE, Yang XP, Scili AG, Corretoro O: Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994;23:865-868.
27. 27. Moreau P, Takase H, Kung CF, Luscher TF: Effect of chronic inhibition of nitric oxide synthesis on vascular structure: remodeling or growth? Arch Mal Coeur Vaiss 1995;88:1141-1143.
28. 28. Moreau P, Takase H, Kung CF, et al: Structure and function of the rat basillar artery during chronic nitric oxide synthase inhibition. Stroke 1995;26:1922-1929.
29. 29. Gohlke R, Stoll M, Lamberty V, et al: Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J Hypertens 1992;(suppl 10):S141-S144.
30. 30. Conrad KP, Joffe GM, Kruszyna H, et al: Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J 1993;7:566-571.
31. 31. Bartholomew B: A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol 1984;22:541-543.
32. 32. Goodman MN, Dluz SM, McElaney MA, et al: Glucose uptake and insulin sensitivity in rat muscle: changes during 3-96 weeks of age. Am J Physiol 1983;244:E94-E100.
33. 33. Jun T, Weidman A: NO-Dependent and -independent elevation of plasma levels of insulin and glucose in rats by L-arginine. Br J Pharmacol 1994;113:345-348.
34. 34. Apiya A, Cohen G, Ignarro I, et al: Nitric oxide regulates insulin secretion in the isolated perfused human pancreas via a cholinergic mechanism. Surgery 1996; 120:322-327.
35. 35. Baron AD, Zhu JS, Marshall S, et al: Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. Am J Physiol 1995;269: E709-E715.
36. G-Methyl-L-Arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. Circ Res 1992;70:607-611.
37. 37. Swislocki A, Fason T, Kaysen GA: Oral administration of the nitric oxide biosynthesis inhibitor, N-nitro-L-arginine-methylester (L-NAME), causes hypertension, but not glucose intolerance or insulin resistance in rats. Am J Hypertens 1995;8:1009-1014.
38. 38. Greenblatt EP, Loeb AL, Longnecker DE: Marked regional heterogeneity in the magnitude of EDRF/NO-mediated vascular tone in awake rats. J Cardiovasc Pharmacol 1993;21:235-240.
39. G-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol 1990; 101:10-12.
40. 40. Huang M, Davis Manning R, LeBlanc MH, Hester RL: Overall hemodynamic studies after the chronic inhibition of endothelial-derived nitric oxide in rats. Am J Hypertens 1995;8:358-364.
41. 41. Vollenweider P, Tappy L, Randin D, et al: Differential effects of hyperinsulinemia abd carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 1993;92:147-154.
42. 42. Anderson EA, Hoffman RP, Balon TW, et al: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87:2246-2252.
43. 43. Steinberg HO, Brechtel G, Johnson A, et al: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1179.
44. 44. Chen Y, Messina J: Dilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol 1996;270:H2120-H2124.
45. 45. Petrie JR, Ueda S, Webb DJ, et al: Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996;93:1331-1333.
46. 46. Cruickshank JK, Anderson NMcF, Wadsworth J, et al: Treating hypertension in black compared with white non-insulin-dependent diabetes: a double blind trial of verapamil and metoprolol. Br Med J 1988;297:1155-1159.
47. 47. Whitcroft I: Do antihypertensive drugs precipitate diabetes? Br Med J 1990;290:322.
48. +2 antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 1991;14:911-914.
49. 49. Weidmann P, Boehlen LM, de Courter M: Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993;125:1498-1513.
50. 50. Gambardella S, Frontoni S, Pellegrinotti M, et al: Carbohydrate metabolism in hypertension: influence of treatment. J Cardiovasc Pharmacol 1993;22(suppl 6): S87-S97.